Showing results (181-190 of 194) with videos related to
Sort By:
Pageof 20
Plos One|May 22, 2020
Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like SignatureMartin P Barr, Steven G Gray, Andreas C Hoffmann, et al.Plos One|January 26, 2013
Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signatureMartin P Barr, Steven G Gray, Andreas C Hoffmann, et al.Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|July 13, 2010
Clinical consensus statement: Diagnosis and management of nasal valve compromiseJohn S Rhee, Edward M Weaver, Stephen S Park, et al.The American Journal of Tropical Medicine and Hygiene|July 29, 2015
Cysticercosis with an Orbital Tropism in TwinsBradford W Lee, Usha R Kumar, Jonathan H Lin, et al.Clinical Colorectal Cancer|October 4, 2005
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancerPetra Kupsch, Bernhard F Henning, Katrin Passarge, et al.British Journal of Cancer|January 18, 2014
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsS Bauer, R A Hilger, T Mühlenberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumorsDirk Strumberg, Heike Richly, Ralf A Hilger, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2006
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumorsH Richly, B F Henning, P Kupsch, et al.Bone Marrow Transplantation|December 14, 2004
Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complicationsD W Beelen, R Trenschel, J Casper, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2000
Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignanciesM E Scheulen, R A Hilger, C Oberhoff, et al.Pageof 20